Michael Dallas Selected Research

VGX-3100

1/2021	Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.
1/2018	Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.
11/2015	Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Dallas Research Topics

Disease

2	Injection Site Reaction 01/2019 - 11/2015
2	Uterine Cervical Dysplasia 01/2018 - 11/2015
2	Erythema 11/2015 - 06/2015
1	COVID-19 01/2022
1	Squamous Intraepithelial Lesions 01/2021
1	Recurrent respiratory papillomatosis 01/2020
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2019
1	Neoplasms (Cancer) 01/2019
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 01/2019
1	Infections 01/2018
1	Myalgia 06/2015
1	Pneumococcal Infections 06/2015
1	Gastroenteritis 12/2009

Drug/Important Bio-Agent (IBA)

3	VaccinesIBA 01/2022 - 06/2015
3	VGX-3100IBA 01/2021 - 11/2015
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	MEDI0457IBA 01/2019
1	AntibodiesIBA 01/2019
1	AntigensIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	DNA VaccinesIBA 11/2015
1	Proteins (Proteins, Gene)FDA Link 11/2015
1	Conjugate VaccinesIBA 06/2015
1	RotaTeqIBA 12/2009

Therapy/Procedure

3	Immunotherapy 01/2021 - 01/2018
1	Therapeutics 01/2020